Loading…
← CockpitCompetitor Analysis › QDEL QuidelOrtho CorporationOpen in the cockpit ↗

QuidelOrtho CorporationQDELCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum weak 29
Mkt cap
$734M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$32.4M
20-day average traded
Fwd P/E
12.0×
forward earnings
ROIC−WACC
-7.1 pp
WACC 6.0%
Hurdle
n/a
no reverse DCF
Next earnings
103 days
17 Feb 2027
Close · USD$10.70
1D-16.7%
1W-19.2%
1M-13.8%
3M-22.2%
6M-0.9%
YTD-62.5%
1Y-60.9%
ATR %11.7%
Beta2.47
52w lowhigh69.9% off high

What QuidelOrtho does

Employees: 6,500

QuidelOrtho at a glance

Size QuidelOrtho (QDEL) is a United States Health Care company (Medical Specialties) with a market value of $734M, the 2447th largest of 3,117 United States companies the cockpit tracks. Shares closed at $10.70 on 6 Nov 2026.

Performance Over six months the shares fell 0.9%, against -9.0% for the median peer and -1.1% for the United States market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue fell 4.6% over the last twelve months (peer median +6.2%); the operating margin is -2.4% (peer median 13.7%).

Valuation It trades at 12.0× forward earnings against a peer median of 20.0× (3rd cheapest of 17).

Capital Return on invested capital runs 7.1 points below its cost of capital (6.0% WACC).

Short interest Short interest is 18.9% of the free float (15 Oct 2026).

Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015011 May 202611 Aug 20266 Nov 2026QDEL 107Peer median 91
Six months, rebased to 100: QuidelOrtho against the median of its 20 peers (local-currency closes).

QuidelOrtho financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.59B$2.73B$2.79B$2.99B$3.26B
Revenue growth—-2%-7%-8%—
Gross profit$959M$1.08B$1.09B$1.28B$1.80B
EBITDA$399M$494M$502M$704M$1.26B
Net income-$369M-$1.13B-$2.05B-$10.1M$549M
Free cash flow-$118M-$83.0M-$112M$70.9M$744M
Capital expenditure$126M$188M$195M$209M$141M
Total debt$3.12B$2.83B$2.68B$2.61B$2.85B

Quarterly statements and history in the cockpit →

QuidelOrtho competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%-10%0%+10%002876300453688410688389MLAB301234SNT300622CTKB491000INMDPACB688085300326301367VREX15017575688236300952QDEL6-month return →1-month return →
Up and to the right = strong over both horizons. QuidelOrtho is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%20×40×002876300453688410688389MLABSNT300622INMD688085300326301367VREX15017575688236300952QDELRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. QuidelOrtho is the large dot.

QuidelOrtho competitors and peer comparison

How QuidelOrtho compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

QuidelOrtho against its 20 peers (data as of 6 Nov 2026)
MeasureQDELPeer medianRank in peer set
1-month return-13.8%+0.5%2nd lowest of 21
6-month return-0.9%-9.0%7th highest of 21
Distance from 52-week high-69.9%-20.0%lowest of 21
Revenue growth (TTM)-4.6%+6.2%5th lowest of 21
Operating margin-2.4%13.7%4th lowest of 21
Forward P/E12.0×20.0×3rd cheapest of 17
ROIC minus cost of capital-7.1 pp+3.9 pp4th lowest of 21
EV / EBITDA9.2×11.0×3rd cheapest of 7
Net debt / EBITDA7.4×-0.4×most indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
QuidelOrtho QDELUnited States$734M-1%-5%-2%12.0×n/an/a
Shenzhen Sunnypol Optoelectornics 002876.SZChina$728M-8%+29%5%41.8×11.1%+14.2%
Jiang Xi Sanxin Medtec 300453.SZChina$741M-5%+12%18%16.1×-2.1%+11.8%
SWS Hemodialysis Care 688410.SSChina$723M-12%+31%19%24.1×16.7%+25.9%
Shenzhen Lifotronic Technology 688389.SSChina$749M-11%+14%13%32.4×13.5%+13.3%
Mesa Laboratories MLABUnited States$718M+23%+3%9%12.6×21.1%+13.2%
Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZChina$750M+177%-14%3%n/a33.5%-0.6%
Synektik SNT.WAPoland$713M+16%+50%24%11.8×0.1%+40.3%
Doctorglasses Chain 300622.SZChina$757M-10%+6%14%24.5×-2.4%+15.7%
Cytek Biosciences CTKBUnited States$758M+26%+5%-22%n/an/an/a
Livsmed 491000.KSSouth Korea$706M-47%+89%-59%n/an/an/a
InMode INMDUnited States$767M-5%-7%18%10.1×-10.5%+12.4%
Pacific Biosciences of California PACBUnited States$701M+60%+2%-102%n/an/an/a
Shanghai Sanyou Medical 688085.SSChina$700M-21%+15%4%50.9×29.1%+6.8%
Shanghai Kinetic Medical 300326.SZChina$698M-7%-28%17%27.4×8.1%-1.9%
BMC Medical 301367.SZChina$780M-13%+37%17%19.8×0.1%+15.6%
Varex Imaging VREXUnited States$783M-10%+5%8%20.3×n/an/a
Shanghai INT Medical Instruments 1501.HKHong Kong$784M-25%+35%21%17.8×-2.1%+23.5%
Japan Lifeline 7575.TJapan$685M+16%+6%19%14.1×-9.7%+2.9%
Beijing Chunlizhengda Medical Instruments 688236.SSChina$684M-21%-13%31%19.1×-5.4%+2.2%
Jiangsu Hanvo Safety Product 300952.SZChina$681M-21%+6%8%47.6×n/an/a

Questions

Which companies are QuidelOrtho's closest peers?
The cockpit's peer set: Shenzhen Sunnypol Optoelectornics (002876.SZ), Jiang Xi Sanxin Medtec (300453.SZ), SWS Hemodialysis Care (688410.SS), Shenzhen Lifotronic Technology (688389.SS), Mesa Laboratories (MLAB), Anhui Hongyu Wuzhou Medical Manufacturer (301234.SZ), Synektik (SNT.WA), Doctorglasses Chain (300622.SZ).
Is QuidelOrtho expensive compared with its peers?
On forward p/e it trades at 12.0× against a peer median of 20.0×, 3rd cheapest of 17 in its peer set.
How has QuidelOrtho stock performed?
Over six months to 6 Nov 2026 the shares returned -0.9% against -9.0% for the median peer; over one year -60.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.